Atopic Dermatitis

New global data suggest children with moderate to severe atopic dermatitis may experience stunted growth due to the effect of their disease on sleep, as well as use of certain therapies.

In a phase 3 trial that featured approximately half of participants with skin of color, tapinarof cream 1.0% provided consistent benefit for patients identified as White, Black, or Asian.

A secondary analysis from TRuE-AD3 shows ruxolitinib cream significantly benefits pediatric atopic dermatitis patient-reported outcomes.

A new analysis of the phase 3 ADORING 3 extension trial involved a large, diverse population and the analysis showed that 91% of eligible participants from previous phases rolled over into this trial.

Lawrence Eichenfield, MD, reviews prescription and at-home care strategies for pediatric atopic dermatitis, as well as the best measures of disease monitoring.

These data suggest that, among children with atopic dermatitis and ADHD or other learning disabilities, an assessment for impairment of their cognitive abilities may need prioritization.

These findings, to be presented at AAAAI, may allow for greater awareness among clinicians when prescribing eczema therapies.

These findings, to be presented at AAAAI, highlight the importance of labeling different cleansing products used by consumers with eczema.

This research also included results from a sub-analysis of non-responders with hand eczema to dupilumab and upadacitinib.

In addition to the newly-accepted BLA in the US, the European Medicines Agency also accepted the drug’s Marketing Authorization Application for both conditions.

In an interview, Andrew Blauvelt, MD, MBA, provides further perspective on the approval of roflumilast topical foam, 0.3% (Zoryve) and full publication of phase 3 STRATUM data.

Melodie Young NP and Andrea Nguyen, PA discuss handling prior authorizations for systemic therapies in AD.

The updated labeling for dupilumab’s use resulted from the first phase 3 trial assessing a biologic within this subgroup of eczema patients.

Expert advanced practice providers in dermatology share practical considerations on implementing novel systemic therapies into clinical practice.

Andrea Nguyen, PA shares insight on selecting the appropriate treatment for different patients with AD.

These data, presented at the Winter Clinical conference, showed that roflumilast cream 0.15% led to positive results for patients with eczema.

These new, positive data from the ADORING Phase 3 development program showed no new safety signals with long-term use as well as a significant reduction in disease burden.

Advanced practice providers in dermatology discuss the key updates on the newly released guidelines on the management of AD and what this means for clinical practice.

Andrea Nguyen, PA reviews the mechanism of action of the biologics available for AD as well as the safety data on these systemic therapies.

The December 2023 month in review for dermatology covers major stories regarding a new FDA approval, several new treatment findings, and news on attitudes toward those with acne.

Expert advanced practice providers in dermatology talk about the different systemic and biologic therapies that are currently available and in development for AD.

Andrea Nguyen, PA, discusses some of the drawbacks she sees with topical corticosteroid treatment in AD in her practice.

These new data highlight the importance of larger trials to evaluate the persistence of this treatment’s efficacy and safety seen here.

Expert dermatologists share clinical pearls for providers treating patients with AD, and discuss the future of AD treatment.

Lisa Swanson, MD, PhD, highlights dermatology biologics coordinators as a resource for getting better access to JAK inhibitors.

Dermatology experts discuss the use of JAK inhibitors in clinical practice, highlighting their own experiences and use of JAKs alongside corticosteroids.

Andrea Nguyen, PA, shares which symptoms are most burdensome to patients with AD.

Expert advanced practice providers in dermatology discuss the diagnosis of atopic dermatitis.

These newly-updated parameters were a response by the ACAAI and the AAAAI to recent evidence that had become visible.

Expert dermatologists speak on shared-decision making between the patient and the provider when it comes to selecting the right therapy for AD.